Fig. 6: The timeline of immunization and overall in vivo work through the terminal point on day 54. | npj Vaccines

Fig. 6: The timeline of immunization and overall in vivo work through the terminal point on day 54.

From: Cyclic di AMP phosphodiesterase nanovaccine elicits protective immunity against Burkholderia cenocepacia infection in mice

Fig. 6

Schematic illustration of mice immunization, sample collection, and B. cenocepacia challenge is shown. Five groups of female BALB/c mice (14 mice/group) were subcutaneously (sc) prime-vaccinated with 6x-His-LY-CS:P NPs, 6x-His-KT-CS:P NPs, or 6x-His-BD-CS:P NPs, and with PBS or adjuvant as their respective controls. Mice (n = 14/group) were intranasally (in) boosted twice on days 14 and 28. On day 42, sera, bronchoalveolar lavage (BAL), and spleens were collected from 7 mice/ group. On day 49, the remaining mice (n = 7/group) were infected intranasally with approximately 1 × 108 colony-forming units (CFUs) of B. cenocepacia. Five days post-infection, lungs were harvested, homogenized, serially diluted, and spread on LB agar plates to determine the bacterial load. The diagram is generated using BioRender (license number JI27JQG39D).

Back to article page